Further to the announcement made on 8 December 2017, the Company is pleased to announce that at the meeting of the Loan Stock holders held earlier today the proposed changes to the terms of the Loan Stock were formally approved. Application has been made for 2,535,947 new ordinary shares of 20p each in the Company (“Ordinary Shares”) to be admitted to trading on AIM, and dealings are expected to commence on 28 December 2017.
The following Directors converted Loan Stock and their resultant holdings are as follows:
| Ordinary Shares issued pursuant to the conversion of Loan Stock | Total Beneficial interest in Ordinary Shares | % of issued share capital | |
| Barrry Mence* | 836,601 | 2,289,177 | 22.9% |
| Andrew Michuda | 58,823 | 88,823 | 0.9% |
| Arif Karimjee* | 35,294 | 85,294 | 0.9% |
| Stuart Silcock** | 261,437 | 538,564 | 5.4% |
*Total beneficial interest in Ordinary Shares, including those held by his wife
**Total beneficial interest in Ordinary Shares, including those of his wife, as well as his interest in Ordinary Shares held in Bare Trust for his grandchildren
The new Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares. The Company's issued share capital now consists of 9,999,378 Ordinary Shares. Accordingly, the figure of 9,999,378 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
For Further Information Contact:
| Barry Mence, Chairman Arif Karimjee, CFO |
Sopheon plc | + 44 (0) 1276 919 560 |
| Carl Holmes / Giles Rolls (corporate finance) Mia Gardener (corporate broking) |
finnCap Ltd | + 44 (0) 20 7220 0500 |
About Sopheon
Sopheon (LSE: SPE) partners with customers to provide complete Enterprise Innovation Management solutions including software, expertise, and best practices, that enable them to achieve exceptional long-term revenue growth and profitability. Sopheon’s Accolade solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle, including strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon’s solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM, operated by the London Stock Exchange.
The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014.